HER2 splice variants and their relevance in breast cancer

Journal of Nucleic Acids Investigation

Volumn 2, Issue 1, 2011, Pages 52-59

  Sasso, Marianna ^a   Bianchi, Francesca ^a   Ciravolo, Valentina ^a   Tagliabue, Elda ^a   Campiglio, Manuela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; ECD; HER2; HER2delta16; Herstatin

Indexed keywords

LAPATINIB; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EARLY CANCER; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HER2 GENE; HERSTATIN GENE; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; P100 GENE; SIGNAL TRANSDUCTION; TUMOR GENE;

EID: 80052220164     PISSN: None     EISSN: 20356005     Source Type: Journal    
DOI: 10.4081/jnai.2011.e8     Document Type: Article

References (82)

1. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B related gene in a human mammary carcinoma. Science 1985;229:974-6.
3. Akiyama T, Kadooka T, Ogawara H, Sakakibara S. Characterization of the epidermal growth factor receptor and the erbB oncogene product by site-specific antibodies. Arch Biochem Biophys 1986;245:531-6.
4. Hung M-C, Schechter AL, Chevray PY, et al. Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. Proc Natl Acad Sci USA 1986;83:261-4.
5. Beerli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 1996;271:6071-6.
6. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptor, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
8. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
10. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
11. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
12. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004;306:1506-7.
13. Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003;22:6570-8.
14. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
15. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta Rev Cancer 1994;1198:165-84.
16. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004;44:195-217.:195-217.
17. Ménard S, Forti S, Castiglioni F, et al. HER2 as a prognostic factor in breast cancer. Oncology 2001;61:67-72.
18. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:102-8.
19. Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 2000;182:150-62.
20. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
21. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and Erb-3 are involved in the induction of mammary tumours in transgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-64.
22. Chan R, Muller WJ, Siegel PM. Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumours. Ann N Y Acad Sci 1999; 889:45-51.
23. Muller WJ, Arteaga CL, Muthuswamy SK, et al. Synergistic interaction of the neu proto-oncogene product and transforming growth factor a in the mammary epithelium of transgenic mice. Mol Cell Biol 1996; 16:5726-36.
24. Li B, Rosen JM, Menamin-Balano J, et al. neu/ERBB2 cooperates with p53-172H during mammary tumourigenesis in transgenic mice. Mol Cell Biol 1997;17:3155-63.
25. Casalini P, Botta L, Ménard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 2001;276:12449-53.
26. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
27. Gennari R, Ménard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumours overexpressing HER2. Clin Cancer Res 2004;10: 5650-5.
28. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375: 377-84.
29. Spector NL, Xia W, Burris H, III, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumour growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23:2502-12.
30. Lackey KE. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr Top Med Chem 2006;6:435-60.
31. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008;19:1068-74.
32. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 2005;23:256s-Abstract 3004.
33. Iwata H, Toi M, Fujiwara Y, et al. Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer. Breast Cancer Symphosium 2006;Abstract1091.
34. Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005.
35. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
36. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
37. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
38. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354: 809-20.
39. Campiglio M, Bufalino R, Sandri M, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011;128:147-54.
40. Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010;10: 711-24.
41. Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247-57.
42. Pupa SM, Ménard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumour cells by proteolytic cleavage. Oncogene 1993;8:2917-23.
43. Arribas J, Borroto A. Protein ectodomain shedding. Chem Rev 2002;102:4627-38.
44. Doherty JK, Bond C, Jardim A, et al. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci U S A 1999;96:10869-74.
45. Azios NG, Romero FJ, Denton MC, et al. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 2001;20:5199-209.
46. Staverosky JA, Muldoon LL, Guo S, et al. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. Clin Cancer Res 2005;11:335-40.
47. Aigner A, Juhl H, Malerczyk C, et al. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 2001;19:2101-11.
48. Payne RC, Allard JW, Anderson-Mauser L, et al. Automated assay for HER-2/neu in serum. Clin Chem 2000;46:175-82.
49. Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 2009;27:1685-93.
50. Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008;113:1294-301.
51. Ali SM, Leitzel K, Lipton A, et al. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials. J Clin Oncol 2009;27:e273.
52. Leary AF, Hanna WM, van de Vijver MJ, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009;27:1694-705.
53. Tse C, Lamy PJ. Clinical utility of serum human epidermal growth factor receptor 2 Extracellular Domain Levels: Stop the Shilly-Shally--It Is Time for a Well-Designed, Large-Scale Prospective Study. J Clin Oncol 2009;27:e286-e287.
54. Ghedini GC, Ciravolo V, Tortoreto M, et al. Role of soluble HER2 extracellular domain in HER2-mediated tumour growth and in response to Trastuzumab. J Cell Physiol 2010;225:256-65.
55. Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering Trastuzumabbased therapy. J Cell Physiol 2011 Apr 4. doi: 10.1002/jcp.22773.[Epub ahead of print]
56. Hu P, Zhou T, Qian L, et al. Sequestering ErbB2 in endoplasmic reticulum by its autoinhibitor from translocation to cell surface: an autoinhibition mechanism of ErbB2 expression. Biochem Biophys Res Commun 2006;342:19-27.
57. Hu P, Feng J, Zhou T, et al. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. J Cell Physiol 2005;205:335-43.
58. Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-8.
59. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112:S53-S67.
60. Jackson-Fisher AJ, Bellinger G, Breindel JL, et al. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res 2008;10:R96.
61. Koletsa T, Kostopoulos I, Charalambous E, et al. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia 2008;10:687-96.
62. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97.
63. Marchini C, Gabrielli F, Iezzi M, et al. The human splice variant HER2delta16 induces rapid tumour onset in a reporter transgenic mouse. PLoS ONE 2011;29; 6:e18727.
64. Castiglioni F, Tagliabue E, Campiglio M, et al. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 2006;13:221-32.
65. Mitra D, Brumlik MJ, Okamgba SU, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther 2009;8:2152-62.
66. Mrhalova M, Kodet R. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1. Neoplasma 2003;50:396-402.
67. Dowsett M, Procter M, Caskill-Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-9.
68. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005;23: 1616-22.
69. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008;123:372-9.
70. Cittelly DM, Das PM, Salvo VA, et al. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumours. Carcinogenesis 2010;31:2049-57.
71. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102:13944-9.
72. Finkle D, Quan ZR, Asghari V, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumours in female murine mammary tumour virus huHER2-transgenic mice. Clin Cancer Res 2004;10:2499-511.
73. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9.
74. Yuan CX, Lasut AL, Wynn R, et al. Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr Purif 2003;29:217-22.
75. Liu PC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006;5:657-64.
76. Pedersen K, Angelini PD, Laos S, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumour growth and metastasis. Mol Cell Biol 2009;29:3319-31.
77. Garcia-Castillo J, Pedersen K, Angelini PD, et al. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J Biol Chem 2009;284:25302-13.
78. Molina MA, Saez R, Ramsey EE, et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002;8:347-53.
79. Saez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31.
80. Scaltriti M, Rojo F, Ocana A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer I 2007;99:628-38.
81. Sperinde J, Jin X, Banerjee J, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 2010;16:4226-35.
82. Scaltriti M, Chandarlapaty S, Prudkin L, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumours coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010; 16:2688-95.